Novo Nordisk A/S (NVO) — closed signal from September 16, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 15, 2025.
Predicted vs. what happened
What happened
Reached 54% of the predicted growth at its peak, without hitting the target.
The thesis — published September 16, 2025
Novo Nordisk's stock has been climbing, helped by its strong position in obesity care. Recent trading shows buyers are more active than usual, and the price has been staying above its recent average price. On 09-16, the company plans to ask the US FDA to approve a higher dose of Wegovy, which could widen its reach. With steady business results and positive mood, a slow, steady rise over the next 3 months looks reasonable.
Primary drivers
- Plan on 09-16 to ask US regulators to approve higher-dose Wegovy
- Price trend is up, recent average price rising, buyers gaining
- Business strength and steady results help the upward trend last
- Big investment funds are buying, helping keep demand firm and steady
How it played out
NVO: target not reached by the window end
Lyra published NVO at 56.8 on 2025-09-16, with expected growth of 18% over a short-term window. The thesis pointed to Novo Nordisk's position in obesity care, an upward price trend, more active buyers, steady business results, fund buying, and a plan on 09-16 to ask US regulators to approve a higher-dose Wegovy.
Inside the window, the stock rose to a peak of 62.32 on 2025-09-19, a 9.7% gain. It stayed below the 67.02 target and never reached it. By 2025-12-15, it ended at 50.37. The thesis partly played out early, but missed the target.
What happened during the window
On 2025-09-18, Novo Nordisk reported trial data for a pill form of Wegovy. The reported weight loss was 16.6% over 64 weeks for patients who adhered to treatment. On 2025-11-24, the company said oral semaglutide did not meet the primary goal in two late-stage Alzheimer's trials.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.